Kimberley J. Reeves

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Hypoxia-associated gene signature for uterine cervical cancer.

Hypoxia-associated gene signature for uterine cervical cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 04, 2026

The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models.

The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models.

Journal: Physics and imaging in radiation oncology

Published: December 03, 2024

Immune effects of α and β radionuclides in metastatic prostate cancer.

Immune effects of α and β radionuclides in metastatic prostate cancer.

Journal: Nature reviews. Urology

Published: July 23, 2024

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.

Journal: Nature reviews. Urology

Published: April 29, 2024

Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation Therapy.

Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation Therapy.

Journal: International journal of radiation oncology, biology, physics

Published: March 12, 2024

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.

Journal: BMJ oncology

Published: September 21, 2023

A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.

A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.

Journal: EBioMedicine

Published: June 19, 2023

Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost.

Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost.

Journal: Frontiers in oncology

Published: April 05, 2023

Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).

Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).

Journal: BMJ open

Published: November 09, 2022

Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.

Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.

Journal: Molecular medicine reports

Published: March 24, 2022

Hypofractionation: less is more?

Hypofractionation: less is more?

Journal: Oncotarget

Published: June 18, 2021

Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.

Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 10, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026